Vitruvian Partners LLP
Long book
$111.8M
Q1 2026
Positions
7
Top-10 weight
100%
concentration
Last quarter
+85.1%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsVitruvian Partners LLP is a diversified fundamental manager, specialised in technology (84% of the long book), running a $111.8M US long book across 7 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: HINGE HEALTH INC-A, MARQETAINC, CARGURUS INC, XOMETRY INC-A, GLOBAL-E ONLINE LTD.
Over the last 9 quarters its long book ran on average 4.8pp per quarter ahead of the S&P 500, beating the index in 3 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-0.7%
Q2 2024
+6.8%
Q3 2024
+38.0%
Q4 2024
-27.0%
Q1 2025
+1.9%
Q2 2025
+1.8%
Q3 2025
-0.7%
Q4 2025
-21.3%
Q1 2026
+85.1%
Sector allocation
Technology 84%
Services media 9%
Healthcare 6%
Long book by quarter
What does Vitruvian Partners own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| HNGE HINGE HEALTH INC-A | Technology | 1.3M | $48.2M | 43.1% | Held |
| CARG CARGURUS INC | Technology | 473.0K | $16.1M | 14.4% | Held |
| XMTR XOMETRY INC-A | Services media | 191.9K | $7.8M | 7.0% | Held |
| GLBE GLOBAL-E ONLINE LTD | Technology | 210.2K | $6.5M | 5.8% | Held |
| MXCT MAXCYTE INC | Healthcare | 5.0M | $3.5M | 3.2% | Held |
| RXST RXSIGHT INC | Healthcare | 278.9K | $1.7M | 1.5% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 11, 2026 | 7 | $111.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 6, 2026 | 7 | $139.2M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 10, 2025 | 7 | $144.2M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 11, 2025 | 7 | $164.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 8, 2025 | 6 | $104.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 11, 2025 | 6 | $116.2M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 12, 2024 | 6 | $257.5M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Jul 18, 2024 | 8 | $340.7M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 8 | $315.4M | canonical | SEC ↗ |